PMID- 32019730
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Apr
TI  - Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center 
      Experience.
PG  - 209-211
LID - S2152-2650(19)32209-8 [pii]
LID - 10.1016/j.clml.2019.11.019 [doi]
AB  - Allogeneic hematopoietic cell transplantation (AHCT) represents the only curative 
      therapy for many hematological malignancies. The graft versus leukemia effect, 
      driven by donor T cells, plays a major role in its curative potential. This 
      effect is sometimes very evident when patients with acute myeloid leukemia and 
      myelodysplasia relapse after AHCT and are treated with donor lymphocyte infusions 
      (DLIs). We retrospectively reviewed the charts of 64 patients who received DLI 
      between 2012 and 2017 in our center. The mean age of the patients was 59 years 
      (range, 34-79). Fifty percent were male (n = 32). The mean follow-up time after 
      AHCT was 50.17 months (range, 8-174). The indication for DLI were disease 
      progression, mixed chimerism, minimal residual disease, and other etiologies in 
      43.8%, 40.7%, 14%, and 1.5% of patients, respectively. The most common diagnosis 
      was acute leukemia, followed by multiple myeloma. Of all patients, 59.4% received 
      a transplant from a related donor, 39% received a transplant from an unrelated 
      donor, and 1.6% received a transplant from a haploidentical donor. 
      Reduced-intensity conditioning AHCT was the most frequent regimen used (53%). DLI 
      was given alone in 79.7% of patients. Prophylactic DLI was given at 30 days after 
      transplantation in patients who received human leukocyte antigen (HLA)-matched 
      related human stem cell transplantation (HSCT) or 45 to 60 days post-transplant 
      in patients receiving haploidentical HSCT or HLA-matched unrelated HSCT. Patients 
      were treated without graft versus host disease (GVHD) prophylaxis. The use of DLI 
      after transplantation remains a feasible procedure with rates of response >60%. 
      Moreover, DLIs are well tolerated with a GVHD rate <10% in our series. We can 
      hypothesize that in our experience the efficacy of this strategy does not rely on 
      the induction of GVHD.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Kerbage, Fouad
AU  - Kerbage F
AD  - Gustave Roussy, Villejuif, France. Electronic address: fouadkerbage@hotmail.com.
FAU - Sakr, Riwa
AU  - Sakr R
AD  - Gustave Roussy, Villejuif, France.
FAU - Lapierre, Valerie
AU  - Lapierre V
AD  - Gustave Roussy, Villejuif, France.
FAU - Alexandrova, Kamelia
AU  - Alexandrova K
AD  - Gustave Roussy, Villejuif, France.
FAU - Coman, Tereza
AU  - Coman T
AD  - Gustave Roussy, Villejuif, France.
FAU - Leroux, Severine
AU  - Leroux S
AD  - Gustave Roussy, Villejuif, France.
FAU - Lucas, Nolwenn
AU  - Lucas N
AD  - Gustave Roussy, Villejuif, France.
FAU - Pilorge, Sylvain
AU  - Pilorge S
AD  - Gustave Roussy, Villejuif, France.
FAU - Solary, Eric
AU  - Solary E
AD  - Gustave Roussy, Villejuif, France.
FAU - Bourhis, Jean-Henri
AU  - Bourhis JH
AD  - Gustave Roussy, Villejuif, France.
FAU - Castilla-Llorente, Cristina
AU  - Castilla-Llorente C
AD  - Gustave Roussy, Villejuif, France.
LA  - eng
PT  - Journal Article
DEP - 20200102
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Female
MH  - Graft vs Host Disease/*prevention & control
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia/*therapy
MH  - *Lymphocyte Transfusion
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*therapy
MH  - Retrospective Studies
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - Allogeneic hematopoietic cell transplantation
OT  - Graft versus host disease
OT  - Hematological malignancies
EDAT- 2020/02/06 06:00
MHDA- 2021/06/01 06:00
CRDT- 2020/02/06 06:00
PHST- 2019/08/12 00:00 [received]
PHST- 2019/10/30 00:00 [revised]
PHST- 2019/11/01 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
PHST- 2020/02/06 06:00 [entrez]
AID - S2152-2650(19)32209-8 [pii]
AID - 10.1016/j.clml.2019.11.019 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):209-211. doi: 
      10.1016/j.clml.2019.11.019. Epub 2020 Jan 2.